Clear Scientific's Executive Vice President presents at the 18th Annual Conference in Behavior, Biology, and Chemistry Translational Research in Substance Use Disorders
- Clear Scientific
- Apr 8
- 1 min read
San Antonio, TX | March 2025
On March 23, 2025, Dr. Xinhua Li, Executive Vice President of Clear Scientific Inc., a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, presented a keynote talk at the 18th Annual Conference in Behavior, Biology, and Chemistry Translational Research in Substance Use Disorders held in San Antonio, Texas. This conference centers on the translational aspects of substance use disorder research among chemists, biologists, and behavioral scientists. The conference’s attendees encompass undergraduate students through senior faculty, chemists, and psychiatrists, providing an exceptional platform for networking across diverse disciplines and fostering the development of novel and innovative approaches to medication development in the field of substance use disorder science.
Dr. Li’s presentation described the benefits and development status of CS-1103, Clear’s first-in-class sequestrant-based therapeutic for rapid treatment of fentanyl, methamphetamine and polydrug intoxication. CS-1103 immediately binds and inactivates threat agents, rapidly reversing their toxic effects and accelerating their clearance from the body.
About Clear Scientific
Clear Scientific, co-founded by Prof. George Whitesides of Harvard University, is pioneering a new paradigm for treatment of conditions and diseases that involve an excess of specific compounds in the body. This approach focuses on development of highly selective, small molecule sequestrants that bind, immediately inactivates intoxicants, and rapidly clear excess compounds from the body.
For more information, visit https://www.clearsci.com.
ความคิดเห็น